6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH
Abeona Therapeutics Inc. Adopts Third Amended and Restated Bylaws
Reports Full Year 2025 Financial Results and Corporate Updates
Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
Reports Third Quarter 2025 Financial Results and Corporate Updates
Reports Second Quarter 2025 Financial Results and Corporate Updates
News, Securities Holder Rights or Indentures, Material Contracts
Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Shareholder votes
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report